Compare HQI & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HQI | ELDN |
|---|---|---|
| Founded | 2002 | 2004 |
| Country | United States | United States |
| Employees | 75000 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.1M | 186.9M |
| IPO Year | 2008 | 2014 |
| Metric | HQI | ELDN |
|---|---|---|
| Price | $16.87 | $3.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $19.00 | $9.00 |
| AVG Volume (30 Days) | 25.3K | ★ 849.8K |
| Earning Date | 11-12-2026 | 11-13-2026 |
| Dividend Yield | ★ 1.47% | N/A |
| EPS Growth | ★ 73.08 | 30.67 |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $30,640,000.00 | N/A |
| Revenue This Year | $0.54 | N/A |
| Revenue Next Year | $5.47 | N/A |
| P/E Ratio | $52.90 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.38 | $1.35 |
| 52 Week High | $20.84 | $4.60 |
| Indicator | HQI | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 49.34 | 66.56 |
| Support Level | $15.28 | $2.63 |
| Resistance Level | $18.49 | $3.18 |
| Average True Range (ATR) | 0.95 | 0.21 |
| MACD | -0.09 | 0.11 |
| Stochastic Oscillator | 48.91 | 77.55 |
HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The company's primary source of revenue is royalty fees based on the operation of its franchised offices.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.